
USD
$0.00
(0.00%
)At Close (As of Dec 11, 2025)
$2.83M
Market Cap
-
P/E Ratio
-119.64
EPS
$96.30
52 Week High
$4.88
52 Week Low
HEALTHCARE
Sector
| Field | Value (USD) |
|---|---|
| Gross Profit | -$337K |
| Total Revenue | $0 |
| Cost Of Revenue | $337K |
| Costof Goods And Services Sold | $337K |
| Operating Income | -$9.6M |
| Selling General And Administrative | $6.5M |
| Research And Development | $2.8M |
| Operating Expenses | $9.3M |
| Investment Income Net | - |
| Net Interest Income | $219 |
| Interest Income | $219 |
| Interest Expense | - |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $337K |
| Income Before Tax | -$9.6M |
| Income Tax Expense | $8.9K |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | -$9.6M |
| Comprehensive Income Net Of Tax | - |
| Ebit | -$9.6M |
| Ebitda | -$9.2M |
| Net Income | -$9.6M |
| Field | Value (USD) |
|---|---|
| Total Assets | $3.1M |
| Total Current Assets | $2.7M |
| Cash And Cash Equivalents At Carrying Value | $2.2M |
| Cash And Short Term Investments | $2.2M |
| Inventory | - |
| Current Net Receivables | - |
| Total Non Current Assets | $348K |
| Property Plant Equipment | - |
| Accumulated Depreciation Amortization Ppe | - |
| Intangible Assets | $42K |
| Intangible Assets Excluding Goodwill | $42K |
| Goodwill | - |
| Investments | - |
| Long Term Investments | - |
| Short Term Investments | - |
| Other Current Assets | $494K |
| Other Non Current Assets | - |
| Total Liabilities | $1.5M |
| Total Current Liabilities | $1.5M |
| Current Accounts Payable | $522K |
| Deferred Revenue | - |
| Current Debt | - |
| Short Term Debt | - |
| Total Non Current Liabilities | $0 |
| Capital Lease Obligations | - |
| Long Term Debt | - |
| Current Long Term Debt | - |
| Long Term Debt Noncurrent | - |
| Short Long Term Debt Total | - |
| Other Current Liabilities | $707K |
| Other Non Current Liabilities | - |
| Total Shareholder Equity | $1.6M |
| Treasury Stock | - |
| Retained Earnings | -$106M |
| Common Stock | $6.8K |
| Common Stock Shares Outstanding | $42K |
| Field | Value (USD) |
|---|---|
| Gross Profit | -$337K |
| Total Revenue | $0 |
| Cost Of Revenue | $337K |
| Costof Goods And Services Sold | $337K |
| Operating Income | -$9.6M |
| Selling General And Administrative | $6.5M |
| Research And Development | $2.8M |
| Operating Expenses | $9.3M |
| Investment Income Net | - |
| Net Interest Income | $219 |
| Interest Income | $219 |
| Interest Expense | - |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $337K |
| Income Before Tax | -$9.6M |
| Income Tax Expense | $8.9K |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | -$9.6M |
| Comprehensive Income Net Of Tax | - |
| Ebit | -$9.6M |
| Ebitda | -$9.2M |
| Net Income | -$9.6M |
Sector: HEALTHCARE
Industry: BIOTECHNOLOGY
Enveric Biosciences Inc. is an innovative pharmaceutical company headquartered in Florida, specializing in the development of cannabinoid-based therapeutics aimed at improving treatment outcomes for cancer patients. Utilizing its extensive expertise in cannabinoid research, Enveric is committed to creating groundbreaking drug candidates that address significant unmet medical needs in oncology, thereby enhancing the quality of life for those affected by cancer. With a robust focus on clinical development, the company is well-positioned to leverage the growing intersection of cannabinoid science and cancer care, striving to redefine therapeutic approaches in a rapidly evolving market.